IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IRL-201104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRL-201104 overview
IRL-201104 is under development for the treatment of asthma, allergies, eosinophilic esophagitis, grass pollen allergy, seasonal allergic rhinitis, food allergy, coronavirus disease 2019 (COVID-19), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome, ARDS Associated to Influenza Infection and atopic dermatitis. The drug candidate is a peptide derived from mycobacterium tuberculosis chaperonin 60.1. It is administered through intravenous and subcutaneous routes.
It was also under development for dermatological indications.
Revolo Biotherapeutics overview
Revolo Biotherapeutics is a biotechnology company. It focuses on revolutionizing the treatment of autoimmune and allergic diseases by resetting the immune system using novel macrophage and monocyte biology. Revolo Biotherapeutic’s products pipeline includes 1104 and 1805, which are designed to modify the immune cascade and potentially lead to superior disease remission for patients. The company’s products are used in treating various diseases including autoimmune and allergic diseases. It caters to the healthcare and pharmaceutical industries. The company was funded by 24 Haymarket (UK), Metellus AG (Switzerland) and Morningside Venture Capital. It operates in the UK and the US. Revolo Biotherapeutics is headquartered in Cambridgeshire, England, the UK.
For a complete picture of IRL-201104’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
